Radiant Medical, Inc. announced the world's first
treatment of a heart attack patient with cool therapy. The patient was
enrolled in an ongoing clinical trial, COOL MI, designed to investigate the
feasibility of cool therapy in heart attack patients. The experimental
procedure is intended to reduce the injury caused by a heart attack by
reducing the heart's need for oxygen and preventing cell death.
Dr. Robert Whitbourn of St. Vincent's Hospital, Melbourne, Australia, was the first to employ cool therapy to treat a heart attack patient. The
treatment involves cooling the heart during and after the attack. A heat
exchange catheter is placed in a large vein leading to the heart. The
catheter cools the blood, which in turn cools the heart. The new therapy may
offer improved outcomes to the more than two million patients worldwide each
year that suffer heart attacks. Hypothermia has long been used as a tissue
protectant during cardiovascular surgery.
Dr. Whitbourn, Director of Coronary Care and Cardiac Research at
St. Vincent's Hospital, performed the treatment. "The procedure went smoothly
and according to plan and the patient is doing well," said Dr. Whitbourn, " I
am excited to be involved with this clinical trial, therapeutic hypothermia
has the potential to significantly improve outcomes for heart attack
The treatment was delivered by Radiant Medical's novel new technology, the SetPoint(TM) Endovascular Temperature Management System. The SetPoint(TM)
System couples a heat exchange catheter with a microprocessor-controlled drive
unit. The drive unit controls the temperature of the catheter and thus
controls the temperature of the heart. The SetPoint(TM) System offers rapid
patient cooling or warming and precise achievement and maintenance of a target
In a press release, Radiant Medical, commented, "This is a
significant milestone for Radiant, the culmination of a lot of hard work by
the Radiant and St. Vincent's teams. We are very pleased to have launched
this exciting clinical trial. The first phase of this study, designed to
assess the feasibility of the treatment, will enroll patients at major U.S.
and International centers. We expect to enroll our first heart attack patient
in the US this week. Dr. Whitbourn and his colleagues are pioneering this
promising new therapy; together we hope to improve the outcomes and quality of
life for heart attack patients throughout the world."